Short answer
Alkermes plc. (ALKS) filed its Q3 2025 10-Q quarterly report on Oct 28, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $394M (up 4.2% year over year) with net income of $83M.
Q3 2025 key financials · XBRL
- Revenue
- $394M
- +4.2% YoY · +0.9% QoQ
- Net income
- $83M
- −10.4% YoY · −5.0% QoQ
- Operating margin
- 22.6%
- EPS (diluted)
- $0.49
- −10.9% YoY · −5.8% QoQ
Source: XBRL data from the Alkermes plc. (ALKS) Q3 2025 10-Q on SEC EDGAR. USD.
Alkermes plc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue increased $16.0M QoQ, driven by higher product sales, partially offset by lower manufacturing and royalty revenue
- Net income from continuing operations $82.8M vs $92.8M YoY Q3, net income decline of $10.0M
- Total expenses rose $31.7M QoQ due to higher R&D and SG&A, partially offset by lower cost of goods sold
- Nine months net income $192.3M vs $226.4M YoY, a decrease of $34.1M due to $36.3M decline in manufacturing and royalty revenues
- Total expenses up $25.8M for nine months, tax provision down $8.7M
Risk Factors
- New acquisition risk from Avadel deal pending H1 2026, subject to shareholder, court, and US antitrust approvals
- Most material update: Added $1.2B Bridge Credit Facility for Avadel acquisition, with leverage covenants and default risks
- Regulatory uncertainty from potential US supplemental tariffs on pharmaceutical imports impacting cost and market volatility
- Operational risk from integration challenges with Avadel including employee retention and cultural differences likely affecting near-term results
- Financial risk: Potential increased borrowing costs if permanent financing for acquisition unavailable, plus restrictive credit covenants on assets and operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Alkermes plc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.